Research / Clinical
Summary
|
|
Diseases/Research Topics
Cancer, Self-renewal, Stem Cells
Chronic myeloproliferative disorders and myelodysplastic syndromes have a propensity to evolve to acute myelogenous leukemia. This progression may be halted if the molecular events involved in disease progression and the stage of hematopoiesis at which they occur are elucidated and systematically blocked.
Since Dr. Jamieson's discovery of candidate cancer stem cells involved in progression of chronic myelogenous leukemia (CML) to acute leukemia, and the molecular events involved in enhancing CML cancer stem cell proliferation and self-renewal, she has devised robust methods to detect cancer stem cells in vivo, thereby permitting a comprehensive assessment of novel cancer stem cell diagnostics and therapeutics. She has applied molecular progenitor profiling, used for the discovery of cancer stem cells in advanced phase CML, to other myeloproliferative disorders and found that a specific mutation in the JAK2 signaling molecule occurs at the stem cell level in polycythemia vera and changes cell fate decisions in primitive hematopoietic cells.
Future studies will involve systematic molecular progenitor profiling combined with global gene expression profiling and a single cell FACS-based phosphoproteomics approach to identify the sequence of molecular events involved in progression of myeloproliferative disorders and myelodysplastic syndromes to acute leukemia with the ultimate aim of designing and testing novel cancer stem cell diagnostic and therapeutic strategies for use in MDS and MPD clinical trials at the Moores Cancer Center.
Update Summary via ONcLINE (password required)
Click here to request a
new or forgotten password
|
